Distinct roles of Mdm2 and Mdm4 in red cell production

被引:56
|
作者
Maetens, Marion
Doumont, Gilles
De Clercq, Sarah
Francoz, Sarah
Froment, Pascal
Bellefroid, Eric
Klingmuller, Ursula
Lozano, Guillermina
Marine, Jean-Christophe
机构
[1] Univ Ghent VIB, Flanders Inst Biotechnol, Lab Mol Canc Biol, B-9052 Ghent, Belgium
[2] Free Univ Brussels VIB, Mol Embryol Lab, Gosselies, Belgium
[3] German Canc Res Ctr, D-6900 Heidelberg, Germany
[4] Univ Texas, MD Anderson Canc Ctr, Grad Sch Biomed Sci, Houston, TX 77030 USA
[5] Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Sect Canc Genet, Houston, TX 77030 USA
关键词
D O I
10.1182/blood-2006-03-013656
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mdm2 and Mdm4 are critical negative regulators of the p53 tumor suppressor. Mdm4-null mutants are severely anemic and exhibit impaired proliferation of the fetal liver erythroid lineage cells. This phenotype may indicate a cell-intrinsic function of Mdm4 in erythropoiesis. In contrast, red blood cell count was nearly normal in mice engineered to express low levels of Mdm2, suggesting that Mdm2 might be dispensable for red cell production. Here, we further explore the tissue-specific functions of Mdm2 and Mdm4 in the erythroid lineage by intercrossing conditional Mdm4 and Mdm2 alleles to an erythroid-specific Cre (Er-GFP-Cre) knock-in allele. Our data show that Mdm2 is required for rescuing erythroid progenitors from p53-mediated apoptosis during primitive erythropoiesis. In contrast, Mdm4 is only required for the high erythropoietic rate during embryonic definitive erythropoiesis. Thus, in this particular cellular context, Mclm4 only contributes to p53 regulation at a specific phase of the differentiation program.
引用
收藏
页码:2630 / 2633
页数:4
相关论文
共 50 条
  • [31] Depletion of Mdm2 and Mdm4 by adenovirus: Molecular mechanism and anticancer therapeutic implication
    Liao, Daiqing
    Zhao, Lisa Y.
    Yang, Heng
    [J]. CANCER RESEARCH, 2011, 71
  • [32] Associations of MDM2 and MDM4 Polymorphisms with Early-Stage Breast Cancer
    Bartnykaite, Agne
    Savukaityte, Aiste
    Ugenskiene, Rasa
    Dauksaite, Monika
    Korobeinikova, Erika
    Gudaitiene, Jurgita
    Juozaityte, Elona
    [J]. JOURNAL OF CLINICAL MEDICINE, 2021, 10 (04) : 1 - 11
  • [33] Tissue-specific differences of p53 inhibition by Mdm2 and Mdm4
    Grier, JD
    Xiong, SB
    Elizondo-Fraire, AC
    Parant, JM
    Lozano, G
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2006, 26 (01) : 192 - 198
  • [34] Downregulation of Mdm2 and Mdm4 enhances viral gene expression during adenovirus infection
    Yang, Heng
    Zheng, Zhi
    Zhao, Lisa Y.
    Li, Qiang
    Liao, Daiqing
    [J]. CELL CYCLE, 2012, 11 (03) : 582 - 593
  • [35] Peptides and peptidomimetics in the p53/MDM2/MDM4 circuitry - a patent review
    Teveroni, Emanuela
    Luca, Rossella
    Pellegrino, Marsha
    Ciolli, Germana
    Pontecorvi, Alfredo
    Moretti, Fabiola
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2016, 26 (12) : 1417 - 1429
  • [36] Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4
    Marine, J-C
    Francoz, S.
    Maetens, M.
    Wahl, G.
    Toledo, F.
    Lozano, G.
    [J]. CELL DEATH AND DIFFERENTIATION, 2006, 13 (06): : 927 - 934
  • [37] MDM2与MDM4抑制剂的研究进展
    李春红
    杜宏金
    温小安
    孙宏斌
    [J]. 中国药科大学学报, 2015, 46 (01) : 1 - 15
  • [38] Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4
    J-C Marine
    S Francoz
    M Maetens
    G Wahl
    F Toledo
    G Lozano
    [J]. Cell Death & Differentiation, 2006, 13 : 927 - 934
  • [39] Double knockdown of MDM4 and MDM2 modulates the antitumor effects of cytotoxic drugs in colon and gastric cancer cells expressing high levels of MDM4
    Imanishi, Mamiko
    Yamamoto, Yoshiyuki
    Endo, Shinji
    Yamato, Kenji
    Hyodo, Ichinosuke
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [40] MDM2和MDM4对P53调控研究进展
    赵婧
    屈艺
    母得志
    [J]. 医学研究杂志, 2011, 40 (10) : 141 - 143